NCT03338816 - ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

January 31, 2019

Study Completion Date

May 31, 2021

Conditions

Acute Hepatic PorphyriaAcute Intermittent PorphyriaPorphyria, Acute IntermittentAcute PorphyriaHereditary Coproporphyria (HCP)Variegate Porphyria (VP)ALA Dehydratase Deficient Porphyria (ADP)

Interventions

DRUG

Givosiran

Givosiran by SC

DRUG

Placebo

Matching placebo (normal saline \[0.9% NaCl\]) by SC

Trial Locations (36)

1431

Clinical Trial Site, Sofia

2050

Clinical Trial Site, Camperdown

3015

Clinical Trial Site, Rotterdam

3050

Clinical Trial Site, Parkville

4066

Clinical Trial Site, Auchenflower

5000

Clinical Trial Site, Odense

10002

Clinical Trial Site, Taipei

10029

Clinical Trial Site, New York

19107

Clinical Trial Site, Philadelphia

27157

Clinical Trial Site, Winston-Salem

30120

Clinical Trial Site, El Palmar

31008

Clinical Trial Site, Pamplona

33305

Clinical Trial Site, Taoyuan

40705

Clinical Trial Site, Taichung

41124

Clinical Trial Site, Modena

48109

Clinical Trial Site, Ann Arbor

72205

Clinical Trial Site, Little Rock

75877

Clinical Trial Site, Paris

77555

Clinical Trial Site, Galveston

80331

Clinical Trial Site, Munich

84112

Clinical Trial Site, Salt Lake City

94143

Clinical Trial Site, San Francisco

98195

Clinical Trial Site, Seattle

02114

Clinical Trial Site, Boston

T6G 2R3

Clinical Trial Site, Edmonton

00290

Clinical Trial Site, Helsinki

09116

Clinical Trial Site, Chemnitz

430-0929

Clinical Trial Site, Hamamatsu

820-8505

Clinical Trial Site, Iizuka

108-0073

Clinical Trial Site, Tokyo

04530

Clinical Trial Site, Mexico City

02-776

Clinical Trial Site, Warsaw

05030

Clinical Trial Site, Seoul

08036

Clinical Trial Site, Barcelona

171 76

Clinical Trial Site, Stockholm

SE5 9RS

Clinical Trial Site, London